Emerald Advisers LLC raised its position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) by 26.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 679,772 shares of the company’s stock after purchasing an additional 141,520 shares during the period. Reata Pharmaceuticals […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) had its price objective raised by Cantor Fitzgerald from $121.00 to $138.00 in a research note published on Monday morning, The Fly reports. The firm currently has an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Reata Pharmaceuticals’ FY2022 earnings at ($8.54) EPS and FY2023 earnings […]